Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Accounts Payables (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Accounts Payables for 17 consecutive years, with $27000.0 as the latest value for Q1 2026.

  • Quarterly Accounts Payables fell 98.37% to $27000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $27000.0 through Mar 2026, down 98.37% year-over-year, with the annual reading at $859000.0 for FY2025, 55.95% down from the prior year.
  • Accounts Payables for Q1 2026 was $27000.0 at Achieve Life Sciences, down from $859000.0 in the prior quarter.
  • The five-year high for Accounts Payables was $2.0 million in Q4 2024, with the low at $27000.0 in Q1 2026.
  • Average Accounts Payables over 5 years is $906647.1, with a median of $656000.0 recorded in 2022.
  • The sharpest move saw Accounts Payables surged 343.97% in 2025, then crashed 98.37% in 2026.
  • Achieve Life Sciences' Accounts Payables stood at $1.7 million in 2022, then crashed by 62.77% to $618000.0 in 2023, then surged by 215.53% to $2.0 million in 2024, then tumbled by 55.95% to $859000.0 in 2025, then tumbled by 96.86% to $27000.0 in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Accounts Payables are $27000.0 (Q1 2026), $859000.0 (Q4 2025), and $1.9 million (Q3 2025).